Test Code LAB0233031 Coagulation Factor VIII Activity Assay, Plasma
Additional Codes
Mayo Test ID |
---|
F8A |
Performing Laboratory
Mayo Clinic Laboratories in RochesterUseful For
Diagnosing hemophilia A
Diagnosing von Willebrand disease when measured with the von Willebrand factor (VWF) antigen and VWF activity
Diagnosing acquired deficiency states
Investigation of prolonged activated partial thromboplastin time
Monitoring infusions of factor VIII replacement during interventional procedures and prophylactic infusions
This test is not useful for inferring carrier status in suspected female carriers of hemophilia A, unless it is 50% of normal (<28% activity in adults).
Testing Algorithm
For information see Hemophilia Testing Algorithm.
Special Instructions
Method Name
Optical Clot-Based
Reporting Name
Coag Factor VIII Activity Assay, PSpecimen Type
Plasma Na CitOrdering Guidance
Coagulation testing is highly complex, often requiring the performance of multiple assays and correlation with clinical information. For that reason, consider ordering a Coagulation Consultation.
Necessary Information
If priority specimen, mark request form, give reason, and request a call-back.
Specimen Required
Specimen Type: Platelet-poor plasma
Patient Preparation: Patient must not be receiving Coumadin (warfarin) or heparin therapy.
Collection Container/Tube: Light-blue top (3.2% sodium citrate)
Submission Container/Tube: Plastic vial
Specimen Volume: 1 mL
Collection Instructions:
1. Specimen must be collected prior to factor replacement therapy.
2. For complete instructions, see Coagulation Guidelines for Specimen Handling and Processing.
3. Centrifuge, transfer all plasma into a plastic vial, and centrifuge plasma again.
4. Aliquot plasma into a plastic vial leaving 0.25 mL in the bottom of centrifuged vial.
5. Freeze plasma immediately (no longer than 4 hours after collection) at -20° C or ideally, at or below -40° C.
Additional Information:
1. Double-centrifuged specimen is critical for accurate results as platelet contamination may cause spurious results.
2. Each coagulation assay requested should have its own vial.
Freeze plasma within 2 hours of collection and submit frozen.
Specimen Minimum Volume
0.5 mL
Specimen Stability Information
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Plasma Na Cit | Frozen | 14 days |
Reject Due To
Gross hemolysis | Reject |
Gross lipemia | Reject |
Gross icterus | Reject |
Reference Values
Adults: 55-200%
Normal, full-term newborn infants or healthy premature infants typically have levels greater than or equal to 40%.*
*See Pediatric Hemostasis References in Coagulation Guidelines for Specimen Handling and Processing.
Interpretation
Mild hemophilia A: 5% to 50% activity
Moderate hemophilia A: 1% to 5% activity
Severe hemophilia A: <1% activity
Congenital deficiency may also occur in combined association with factor V deficiency.
Liver disease usually causes an increase of factor VIII activity.
Acquired deficiencies of factor VIII have been associated with myeloproliferative or lymphoproliferative disorders (acquired von Willebrand disease: VWD), inhibitors of factor VIII (autoantibodies, postpartum conditions, etc), and intravascular coagulation and fibrinolysis.
Levels may be decreased with von Willebrand factor in VWD.
Day(s) Performed
Monday through Saturday
Report Available
1 to 3 daysSpecimen Retention Time
7 daysTest Classification
This test has been modified from the manufacturer's instructions. Its performance characteristics were determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
85240
LOINC Code Information
Test ID | Test Order Name | Order LOINC Value |
---|---|---|
F8A | Coag Factor VIII Activity Assay, P | 3209-4 |
Result ID | Test Result Name | Result LOINC Value |
---|---|---|
F8A | Coag Factor VIII Activity Assay, P | 3209-4 |
Forms
If not ordering electronically, complete, print, and send a Coagulation Test Request (T753) with the specimen.